Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 8;9(7):e101899.
doi: 10.1371/journal.pone.0101899. eCollection 2014.

miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma

Affiliations

miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma

Rut Tejero et al. PLoS One. .

Abstract

Background: Several treatments in non-small cell lung cancer (NSCLC) are histology-dependent, and the need for histology-related markers is increasing. MicroRNAs (miRNAs) are promising molecular markers in multiple cancers and show differences in expression depending on histological subtype. The miRNA family miR-200 has been associated with the regulation of epithelial-mesenchymal (EMT)/mesenchymal-epithelial transition (MET). EMT involves profound phenotypic changes that include the loss of cell-cell adhesion, the loss of cell polarity, and the acquisition of migratory and invasive properties that facilitates metastasis. A dual role for the miR-200 family in the prognosis of several tumors has been related to tumor cell origin. However, the prognostic role and function of miR-200 family in early-stage NSCLC adenocarcinoma and squamous cell carcinoma (SCC) have not been well established.

Methods: miRNA expression was determined using TaqMan assays in 155 tumors from resected NSCLC patients. Functional studies were conducted in three NSCLC cell lines: H23, A-549 and HCC-44.

Results: High miR-200c expression was associated with shorter overall survival (OS) in the entire cohort (p = 0.024). High miR-200c (p = 0.0004) and miR-141 (p = 0.009) expression correlated with shorter OS in adenocarcinoma - but not in SCC. In the multivariate analysis, a risk score based on miR-141 and miR-200c expression emerged as an independent prognostic factor for OS in the entire cohort (OR, 2.787; p = 0.033) and in adenocarcinoma patients (OR, 10.649; p = 0.002). Functional analyses showed that miR-200c, was related to mesenchymal-epithelial transition (MET) and affected cell migration and E-cadherin levels, while overexpression of miR-141 reduced KLF6 protein levels and produced an increase of secretion of VEGFA in vitro (H23, p = 0.04; A-549, p = 0.03; HCC-44, p = 0.02) and was associated with higher blood microvessel density in patient tumor samples (p<0.001).

Conclusion: High miR-141 and miR-200c expression are associated with shorter OS in NSCLC patients with adenocarcinoma through MET and angiogenesis.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. OS analysis in the entire cohort.
OS according to (A) miR-200c expression levels in the entire cohort (N = 155); (B) miR-200c expression levels in stage I patients (N = 94); and (C) miR-141 expression levels in stage I patients (N = 94).
Figure 2
Figure 2. OS analysis by histological subtype.
Overall survival according to (A) miR-200c expression levels in patients with SCC (N = 70); (B) miR-141 expression levels in patients with SCC (N = 70); (C) miR-200c expression levels in patients with adenocarcinoma (N = 73); and (D) miR-141 expression levels in patients with adenocarcinoma (N = 73).
Figure 3
Figure 3. OS in 73 patients with adenocarcinoma according to the miR-141/miR-200c risk score.
Figure 4
Figure 4. Overexpression of miR-200c affects cell migration.
(A) After 36 or 48h of transfection with pre-miRNAs in the NSCLC cell lines, cell migration was measured by in vitro scratch assay. High levels of miR-200c reduced cell migration in comparison with control in all cell lines (H23, p = 0.005; A-549, p = 0.0085; HCC-44, p = 0.013), while high levels of miR-141 reduced cell migration only in A-549 (p = 0.04). (B) E-cadherin levels were evaluated by immunohistochemistry and increased levels were observed in cells transfected with pre-miR-200c in comparison with those transfected with pre-miR-141 or pre-miR-control in all three cell lines.
Figure 5
Figure 5. Overexpression of miR-141 negatively regulates KLF6, leading to increased VEGFA levels in vitro, and is related to higher microvessel density in patient samples.
(A) Immunoblotting of KLF6 in cells transfected with pre-miR-Negative Control or pre-miR-141/200c. miR-141 significantly reduced KLF6 protein level in the three cell lines. (B) After 48 h of transfection with pre-miRNAs in hypoxic conditions, VEGFA concentration in the culture supernatant was measured by ELISA. All results represent the mean ± SEM from 3 independent experiments. (C) A total of 29 adenocarcinoma tumor tissue sections were analyzed by immunohistochemistry with CD34+ as vessel marker; two representative cases with high/low levels of miR-141 are shown. (D) Significant differences in blood microvessel density between adenocarcinomas with high levels of miR-141 and those with low levels of miR-141 were observed (p<0.001).

References

    1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: a cancer journal for clinicians. - PubMed
    1. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, et al. (2011) Non-small-cell lung cancer. The Lancet 378: 1727–1740. - PubMed
    1. Travis WD (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart: Iarc.
    1. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, et al. (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. The oncologist 14: 253–263. - PubMed
    1. Patel J, Hensing T, Villafor V, Hart E, Bonomi P (2007) Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results. J Clin Oncol 25: 7601.

Publication types

MeSH terms